NASDAQ$GILD
Gilead Sciences Inc · Q1 2025 earnings
Q1 2025 earnings · · After market close · Investor relations
Briefing
Gilead reported Q1 2025 total revenues of $6.67B with net income of $1.32B and diluted EPS of $1.04.
Total revenues were $6.67 billion for the quarter ended March 31, 2025, roughly flat year over year as lower Veklury sales were offset by HIV and liver disease growth. Net income attributable to Gilead was $1.32 billion versus a year-ago loss; diluted EPS was $1.04. Medicare Part D redesign affected product sales mix.
- Q1 total revenues $6.67B (flat YoY).
- Net income $1.32B; diluted EPS $1.04 vs prior-year loss.
- HIV and liver disease sales partially offset Veklury decline.
- Oncology and partnership economics drive quarterly volatility.
Headline financials
Revenue & EPS history
Gilead Sciences · Revenue · Quarterly
$6.67B
Revenue by segment
Gilead Sciences · $6.14B total across 3 segments · Q3 2023
- HIV$4.67B+4.0%76.0%
- Oncology$769M+327.2%12.5%
- Liver Disease$706M—11.5%
Forward guidance
The quarterly filing discusses operating priorities, liquidity, and sector-specific risks.
Tailwinds
- Management outlines strategic priorities and capital allocation.
- Segment commentary supports the earnings narrative.
Headwinds
- Macro, rates, or input costs may pressure margins.
- One-time items can affect year-over-year comparability.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q1 2025
+0.2%
Avg return
Earnings day
-0.2%
Avg return
5 days after
-0.4%
Avg return
30 days after
44%
32 / 73 earnings
Positive
+11.9%
Q3 2022
Best reaction
-12.4%
Q1 2016
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -0.5% | -1.5% | -3.4% | |
| Q4 2025 | +5.8% | +5.3% | -1.5% | |
| Q3 2025 | +3.1% | +3.5% | +6.2% | |
| Q2 2025 | +8.3% | +8.9% | +4.3% | |
| Q1 2025 | -2.8% | +0.4% | +1.1% | |
| Q4 2024 | +7.5% | +8.3% | +15.9% | |
| Q3 2024 | +8.5% | +7.5% | +2.1% | |
| Q2 2024 | -0.5% | -0.0% | +6.4% | |
| Q1 2024 | -2.5% | -2.8% | -2.1% | |
| Q4 2023 | -3.0% | -4.0% | -4.0% | |
| Q3 2023 | -4.0% | -6.4% | -3.8% | |
| Q2 2023 | +4.0% | +5.8% | +1.3% | |
| Q1 2023 | -1.8% | -3.9% | -7.9% | |
| Q4 2022 | +0.6% | +2.4% | -3.5% | |
| Q3 2022 | +11.9% | +12.0% | +21.8% | |
| Q2 2022 | +4.5% | +2.5% | +9.0% | |
| Q1 2022 | -3.7% | -2.0% | +5.2% | |
| Q4 2021 | -4.2% | -7.0% | -10.1% | |
| Q3 2021 | -2.8% | -1.3% | +5.2% | |
| Q2 2021 | -2.5% | -0.3% | +1.7% | |
| Q1 2021 | -1.5% | +1.9% | +2.6% | |
| Q4 2020 | +6.1% | +4.3% | +0.2% | |
| Q3 2020 | -2.5% | -2.5% | +0.0% | |
| Q2 2020 | -4.8% | -2.9% | -10.6% | |
| Q1 2020 | -3.8% | -4.8% | -6.4% | |
| Q4 2019 | -0.7% | +3.8% | +14.7% | |
| Q3 2019 | -4.9% | -4.7% | -2.0% | |
| Q2 2019 | -3.5% | -4.3% | -6.1% | |
| Q1 2019 | +3.5% | +2.4% | -4.0% | |
| Q4 2018 | -3.4% | -3.7% | -10.2% | |
| Q3 2018 | +2.5% | +5.9% | -2.1% | |
| Q2 2018 | +0.7% | -1.7% | -5.2% | |
| Q1 2018 | -7.4% | -9.4% | -6.7% | |
| Q4 2017 | +5.6% | +1.2% | +2.2% | |
| Q3 2017 | -3.5% | -6.2% | -9.3% | |
| Q2 2017 | +1.7% | +3.2% | +0.1% | |
| Q1 2017 | -1.3% | -0.5% | -5.1% | |
| Q4 2016 | -7.7% | -8.3% | -5.5% | |
| Q3 2016 | -1.5% | -1.6% | -1.1% | |
| Q2 2016 | -6.4% | -8.2% | -7.0% | |
| Q1 2016 | -12.4% | — | — | |
| Q4 2015 | +2.8% | — | — | |
| Q3 2015 | -0.5% | — | — | |
| Q2 2015 | +4.7% | — | — | |
| Q1 2015 | +2.6% | — | — | |
| Q4 2014 | -7.3% | — | — | |
| Q3 2014 | -1.7% | — | — | |
| Q2 2014 | +1.4% | — | — | |
| Q1 2014 | +3.2% | — | — | |
| Q4 2013 | -0.9% | — | — | |
| Q3 2013 | +5.7% | — | — | |
| Q2 2013 | +4.5% | — | — | |
| Q1 2013 | +10.0% | — | — | |
| Q4 2012 | -0.0% | — | — | |
| Q3 2012 | +3.0% | — | — | |
| Q2 2012 | +8.4% | — | — | |
| Q1 2012 | -0.8% | — | — | |
| Q4 2011 | +1.6% | — | — | |
| Q3 2011 | +0.4% | — | — | |
| Q2 2011 | -1.6% | — | — | |
| Q1 2011 | +0.4% | — | — | |
| Q4 2010 | -1.1% | — | — | |
| Q3 2010 | -1.2% | — | — | |
| Q2 2010 | -0.1% | — | — | |
| Q1 2009 | +2.3% | — | — | |
| Q1 2010 | +0.0% | — | — | |
| Q4 2007 | -0.2% | — | — | |
| Q4 2009 | -0.2% | — | — | |
| Q3 2009 | +5.4% | — | — | |
| Q3 2008 | +5.4% | — | — | |
| Q4 2008 | -5.0% | — | — | |
| Q2 2008 | -5.0% | — | — | |
| Q2 2009 | -5.0% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro